In other research, a bi-shRNAfurin/GM-CSF incorporated autologous HCC cell vaccine, FANGTM, stabilized PLC for over 4 months in five patients during a phase I trial, with four patients experiencing more than 2 years’ survival, which surpassed the 7.9 month median survival rate of sorafenib in a phase III trial [23, 30]. This evidence concerns the gene CSF2 and hepatocellular carcinoma.